Late Friday, Edwards Lifescieces announced that it is acquiring CardiAQ Valve Technologies, a maker of transcather mitral valve replacement valves, for about $400 million, including a $350 million ...
Edwards Lifesciences’ SAPIEN M3 mitral valve replacement system has become the first transcatheter therapy utilizing a transseptal approach to snag FDA approval in the U.S. for the treatment of mitral ...
After snaring the U.S. FDA’s approval for the Evoque tricuspid valve device, Edwards Lifesciences Corp. petitioned the Centers for Medicare & Medicaid Services for a national coverage determination ...
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced it has exercised its option to acquire Innovalve Bio Medical Ltd., an early-stage transcatheter mitral valve ...
For patients with significant mitral regurgitation (MR) who are unsuitable for surgical intervention or transcatheter edge-to-edge repair (TEER), transcatheter mitral valve replacement (TMVR) appears ...
DUBLIN, Feb. 12, 2021 /PRNewswire/ -- The "Transcatheter Treatment: Procedures and Heart Valve Market" report has been added to ResearchAndMarkets.com's offering. Transcatheter treatment includes ...
PARIS, France—Final, 5-year results of the MITRAL trial continue to support transcatheter mitral valve replacement (TMVR) in patients with failing bioprostheses or prosthetic rings, and with mitral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results